HomeNew PDE Inhibitors

New PDE Inhibitors

Catalog No. Product Name Information
E1566 Ensifentrine Ensifentrine (RPL-554) is a first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and PDE4 with IC50 values of 0.4 nM and 1479 nM, respectively. Ensifentrine also inhibits lipopolysaccharide-induced tumor necrosis factor alpha release from human monocytes in a concentration-dependent manner. Ensifentrine demonstrates bronchoprotective and anti-inflammatory activities and can be used for chronic obstructive pulmonary disease (COPD) research.
E8284 PM534 PM534 is a potent microtubule-targeting agent (MTA) that binds the colchicine-binding domain (CBD) and inhibits tubulin assembly with IC50 values ranging from 0.8 to 3.2 nM. It also significantly inhibits tumor growth in mouse xenograft models of human non-small cell lung cancer.
E4986 Mirodenafil Mirodenafil (SK3530) is a second-generation, highly selective inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.34 nM, primarily used in the treatment of erectile dysfunction (ED).
E4793 Bucladesine calcium Bucladesine calcium (Dibutyryl-cAMP Calcium Salt, DBcAMP calcium salt) is a cell-permeable analog of cyclic AMP. It serves as a potent activator of protein kinase A (PKA) and mimics the effects of endogenous cAMP. It also inhibits phosphodiesterase (PDE) activity, with the potential to treat congestive heart failure, wound healing, and inflammation.
E4924 Anagrelide Anagrelide(BL416201), an imidazoquinazoline derivative, is an inhibitor of phosphodiesterase type III (PDEIII) with IC50 of 36 nM, which acts as an antithrombotic and platelet-reducing agent.
≡ All PDE Inhibitors